Citations

Showing 10 of 108152 citations.

Use of an advanced collagen matrix dressing on patients with complex chronic lower extremity ulcers: A case series
Alavi, Afsáneh , Archer, Jeannine , Coutts, Patricia, Alavi, A

Mayo Clinic

SAGE Open Medical Case Reports | May 13, 2021 | Volume: 9 | Issue: No issue available | Pages: No page available

10.1177/2050313x211013684 | PMID 34035916 Get It

The objective of this case series was to assess the wound healing effectiveness of a collagen matrix wound dressing containing partially denatured collagen, carboxymethyl cellulose, alginate and ethylenediaminetetraacetic acid in chronic lower extremity ulcers. A total of nine patients with refractory lower extremity ulcers were treated with the collagen contact layer in addition to standard of care. Wound healing progress was measured at 2, 4 and 8 weeks. An average decrease in wound size of 73% was achieved across patients at week 8, with complete healing in two patients. The intervention was easy to use and well tolerated by patients. The results of this study, although preliminary, suggest that the advanced collagen matrix dressing represents an effective and safe treatment strategy for healing refractory chronic lower extremity ulcers of varying etiologies. Further investigation is needed to evaluate efficacy in a larger randomized clinical trial with focus on cost-effectiveness and impact on patient’s quality-of-life.
Knowledge gaps in Alzheimer's disease immune biomarker research
Morgan, David , Mielke, Michelle M.

Mayo Clinic

Alzheimer's & Dementia | May 13, 2021 | Volume: 17 | Issue: 12 | Pages: 2030-2042

10.1002/alz.12342 | PMID 33984178 Get It

AbstractConsiderable evidence has accumulated implicating a role for immune mechanisms in moderating the pathology in Alzheimer's disease dementia. However, the appropriate therapeutic target, the appropriate direction of manipulation, and the stage of disease at which to begin treatment remain unanswered questions. Part of the challenge derives from the absence of any selective pressure to develop a coordinated beneficial immune response to severe neural injury in adults. Thus, immune responses to the prevailing stimuli are likely to contain both beneficial and detrimental components. Knowledge gaps include: (1) how a biomarker change relates to the underlying biology, (2) the degree to which pathological stage group differences reflect a response to pathology versus trait differences among individuals regulating risk of developing pathology, (3) the degree to which biomarker levels are predictive of subsequent changes in pathology and/or cognition, and (4) experimental manipulations in model systems to determine whether differences in immune biomarkers are causally related to pathology.
Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease
Libiger, Ondrej , Shaw, Leslie M. , Watson, Mark H., Umaña, Kelly L., Biarnes, Michael C., Canet‐Avilés, Rosa M., Breton, Yannick‐André, Cortes, Laetitia, Chelsky, Daniel , Spellman, Daniel S. , Baker, Susan , Raghavan, Nandini, Potter, William Z., (ADNI), Alzheimer's Disease Neuroimaging Initiative, Rosenbaugh, Erin G. , Nairn, Angus C. , Canet-Aviles, Rosa, Jack, Clifford R. , (ADNI), Alzheimer's Disease Neuroimaging Initiative

Mayo Clinic

Alzheimer's & Dementia | May 13, 2021 | Volume: 17 | Issue: 12 | Pages: 1976-1987

10.1002/alz.12353 | PMID 33984181 Get It

Abstract Introduction: Biomarkers that reflect pathologic processes affecting neuronal function during preclinical and early stages of Alzheimer's disease (AD) are needed to aid drug development. Methods: A targeted, stable isotope, quantitative mass spectrometry‐based investigation of longitudinal changes in concentrations of previously identified candidate biomarkers was performed in cerebrospinal fluid (CSF) of Alzheimer's Disease Neuroimaging Initiative participants who were classified as cognitively normal (CN; n = 76) or with mild cognitive impairment (MCI; n = 111) at baseline. Results: Of the candidate biomarkers, the CSF concentration of neuronal pentraxin 2 (NPTX2), a protein involved in synaptic function, exhibited rates of change that were significantly different between three comparison groups (i.e., CN vs. MCI participants; AD pathology positive vs. negative defined by phosphorylated tau181/amyloid beta1‐42 ratio; and clinical progressors vs. non‐progressors). The rate of change of NPTX2 also significantly correlated with declining cognition. Discussion: CSF NPTX2 concentration is a strong prognostic biomarker candidate of accelerated cognitive decline with potential use as a therapeutic target.
New pathological illuminations on 3D transillumination transesophageal echocardiography imaging
Chao, Chieh‐Ju , Mandale, Deepa, Naqvi, Tasneem Z. , Mandale, Deepa R, Chao, Chieh-Ju

Mayo Clinic

Echocardiography | May 13, 2021 | Volume: 38 | Issue: 6 | Pages: 1070-1073

10.1111/echo.15060 | PMID 33982822 Get It

AbstractThe use of 3D technology has significantly improved the diagnostic accuracy of echocardiography by overcoming the limitation of 2D echocardiography. Transillumination 3D image post processing technique enhances shadows and contrast of cardiac structures with a movable virtual light source improving further the clarity and detail provided by conventional 3D imaging. In this report, we present 3 cases, one of mobile atherosclerotic aortic root plaque, another of small thrombi on ICD lead, and a third case of bicuspid aortic valve perforation due to infective endocarditis in whom TEE 3D transillumination further improved the diagnostic quality of conventional 3D imaging and lead to accurate clinical diagnosis.
Implementation of free breathing respiratory amplitude‐gated treatments
Hickling, Susannah , Veres, Andrew J., Hickling, Susannah V, Moseley, Douglas J, Grams, Michael P. , Moseley, Douglas , Moseley, D

Mayo Clinic

Journal of Applied Clinical Medical Physics | May 13, 2021 | Volume: 22 | Issue: 6 | Pages: 119-129

10.1002/acm2.13253 | PMID 33982875 Get It

AbstractPurposeThe purpose of this study was to provide guidance in developing and implementing a process for the accurate delivery of free breathing respiratory amplitude‐gated treatments.MethodsA phase‐based 4DCT scan is acquired at time of simulation and motion is evaluated to determine the exhale phases that minimize respiratory motion to an acceptable level. A phase subset average CT is then generated for treatment planning and a tracking structure is contoured to indicate the location of the target or a suitable surrogate over the planning phases. Prior to treatment delivery, a 4DCBCT is acquired and a phase subset average is created to coincide with the planning phases for an initial match to the planning CT. Fluoroscopic imaging is then used to set amplitude gate thresholds corresponding to when the target or surrogate is in the tracking structure. The final imaging prior to treatment is an amplitude‐gated CBCT to verify both the amplitude gate thresholds and patient positioning. An amplitude‐gated treatment is then delivered. This technique was commissioned using an in‐house lung motion phantom and film measurements of a simple two‐field 3D plan.ResultsThe accuracy of 4DCBCT motion and target position measurements were validated relative to 4DCT imaging. End to end testing showed strong agreement between planned and film measured dose distributions. Robustness to interuser variability and changes in respiratory motion were demonstrated through film measurements.ConclusionsThe developed workflow utilizes 4DCBCT, respiratory‐correlated fluoroscopy, and gated CBCT imaging in an efficient and sequential process to ensure the accurate delivery of free breathing respiratory‐gated treatments.
Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1
Frishberg, Yaacov, Groothoff, Jaap W. , Hulton, Sally‐Anne, Magen, Daniella , Harambat, Jérôme, Hoff, William G. van’t, Lorch, Ulrike , Milliner, Dawn S. , Haslett, Patrick , Garg, Pushkal, Vaishnaw, Akshay, Talamudupula, Sandeep, Lu, Jiandong , Habtemariam, Bahru, Erbe, David V., McGregor, Tracy L., Cochat, Pierre , collaborators, on behalf of the study, Garrelfs, Sander F. , Magen, Daniella , Deschênes, Georges , Harambat, Jérôme , Lieske, John C. , collaborators, on behalf of the study

Mayo Clinic

Clinical Journal of the American Society of Nephrology | May 13, 2021 | Volume: 16 | Issue: 7 | Pages: 1025-1036

10.2215/cjn.14730920 | PMID 33985991 Get It

Background and objectives In the rare disease primary hyperoxaluria type 1, overproduction of oxalate by the liver causes kidney stones, nephrocalcinosis, kidney failure, and systemic oxalosis. Lumasiran, an RNA interference therapeutic, suppresses glycolate oxidase, reducing hepatic oxalate production. The objective of this first-in-human, randomized, placebo-controlled trial was to evaluate the safety, pharmacokinetic, and pharmacodynamic profiles of lumasiran in healthy participants and patients with primary hyperoxaluria type 1. Design, setting, participants, & measurements This phase 1/2 study was conducted in two parts. In part A, healthy adults randomized 3:1 received a single subcutaneous dose of lumasiran or placebo in ascending dose groups (0.3–6 mg/kg). In part B, patients with primary hyperoxaluria type 1 randomized 3:1 received up to three doses of lumasiran or placebo in cohorts of 1 or 3 mg/kg monthly or 3 mg/kg quarterly. Patients initially assigned to placebo crossed over to lumasiran on day 85. The primary outcome was incidence of adverse events. Secondary outcomes included pharmacokinetic and pharmacodynamic parameters, including measures of oxalate in patients with primary hyperoxaluria type 1. Data were analyzed using descriptive statistics. Results Thirty-two healthy participants and 20 adult and pediatric patients with primary hyperoxaluria type 1 were enrolled. Lumasiran had an acceptable safety profile, with no serious adverse events or study discontinuations attributed to treatment. In part A, increases in mean plasma glycolate concentration, a measure of target engagement, were observed in healthy participants. In part B, patients with primary hyperoxaluria type 1 had a mean maximal reduction from baseline of 75% across dosing cohorts in 24-hour urinary oxalate excretion. All patients achieved urinary oxalate levels ≤1.5 times the upper limit of normal. Conclusions Lumasiran had an acceptable safety profile and reduced urinary oxalate excretion in all patients with primary hyperoxaluria type 1 to near-normal levels. Clinical Trial registry name and registration number: Study of Lumasiran in Healthy Adults and Patients with Primary Hyperoxaluria Type 1, NCT02706886
Role of highly sensitive nucleic acid amplification testing for plasma cytomegalovirus DNA load in diagnosis of cytomegalovirus gastrointestinal disease among kidney transplant recipients
Taksinwarajarn, Touchapong, Sobhonslidsuk, Abhasnee , Kantachuvesiri, Surasak , Cheungpasitporn, Wisit , Bruminhent, Jackrapong , group, the Ramathibodi Transplant Infectious Diseases (RTID), Bruminhent, Jackrapong , Cheungpasitporn, Wisit , Thongprayoon, Charat , group, the Ramathibodi Transplant Infectious Diseases (RTID)

Mayo Clinic

Transplant Infectious Disease | May 13, 2021 | Volume: 23 | Issue: 4 | Pages: No page available

10.1111/tid.13635 | PMID 33982825 Get It

AbstractBackgroundHigh plasma cytomegalovirus (CMV) DNA load is generally associated with CMV tissue‐invasive disease in solid organ transplant recipients. However, some tissue‐invasive diseases, especially CMV gastrointestinal (GI) disease, have undetectable to very low plasma CMV DNA loads. Highly sensitive nucleic acid amplification testing (NAAT) has been increasingly used to quantify low‐level CMV DNA loads. Our primary objective was to investigate the epidemiology of CMV GI disease and evaluate the validity of plasma CMV NAAT for the diagnosis of CMV GI disease in kidney transplant (KT) recipients.MethodsWe conducted a retrospective study of all KT recipients who developed CMV GI disease from January 2016 to December 2018. Plasma CMV DNA load was measured using real‐time PCR. The cut‐off value of plasma CMV DNA load for diagnosing and risk factors of CMV GI disease were analyzed.ResultsA total 17 (3.4%) cases of CMV GI disease occurred in 494 KT recipients. Fifteen (88%) patients had CMV D + /R + serostatus. Fourteen (82%) patients developed CMV GI disease within 6 months after KT. Plasma CMV DNA loads were detectable in all (100%) patients with a median load 11,102 (IQR 2,935‐107,160) IU/ml. A plasma CMV DNA load of 4,063 IU/ml was established as al cut‐off for diagnosing CMV GI disease (AUC 0.74, sensitivity 76.5%, specificity 70%, PPV 68, NPV 78). In multivariate analysis, prolonged cold ischemic time (HR 1.14, 95% CI 1.05‐1.23, P = .002) and CMV D + /R ‐ serostatus (HR 9.31, 95% CI 2.12‐40.74, P = .003) were associated with CMV GI disease.ConclusionsUsing highly sensitive NAAT could potentially assist in the diagnosis of CMV GI disease in a CMV D + /R + serostatus setting. KT recipients with CMV seromismatch and prolonged cold ischemic time are at higher risk of CMV GI disease.
Relationship Between Rheumatoid Arthritis and Pulmonary Function Measures on Spirometry in the UK Biobank
Prisco, Lauren, Wang, Jiaqi , Hobbs, Brian D. , Huang, Weixing , Martin, Lily W., Kronzer, Vanessa L. , Huang, Sicong , Silverman, Edwin K. , Doyle, Tracy J. , Sparks, Jeffrey A. , Kronzer, Vanessa L , Huang, Sicong , Sparks, Jeffrey A , Hobbs, Brian D , Moll, Matthew , Cho, Michael H.

Mayo Clinic

Arthritis & Rheumatology | May 13, 2021 | Volume: 73 | Issue: 11 | Pages: 1994-2002

10.1002/art.41791 | PMID 33982900 Get It

ObjectiveTo investigate the independent relationship of rheumatoid arthritis (RA) to the type and severity of pulmonary patterns on spirometry compared to the pulmonary patterns in general population controls.MethodsIn this cross‐sectional study, we investigated the association of RA with pulmonary function measures on spirometry among subjects in the UK Biobank who underwent spirometry for research purposes. RA cases were identified based on self‐report and current disease‐modifying antirheumatic drug/glucocorticoid use. Controls were subjects without RA from the general population. Outcome measures included continuous forced expiratory volume in 1 second percent predicted (FEV1%) and forced vital capacity percent predicted (FVC%), type of spirometric pattern (restrictive or obstructive), and severity of the restrictive or obstructive pattern. We used multivariable regression to estimate the effects in RA cases compared to the effects in controls, adjusting for age, sex, body mass index, and smoking status/pack‐years.ResultsAmong 350,776 analyzed subjects who underwent spirometry (mean age 56.3 years; 55.8% female; 45.5% ever smokers), we identified 2,008 cases of treated RA. In multivariable analyses, RA was associated with lower FEV1% (β = –2.93 [95% confidence interval (95% CI) –3.63, –2.24]), FVC% (β = –2.08 [95% CI –2.72, –1.45]), and FEV1/FVC (β = –0.008 [95% CI –0.010, –0.005]) compared to controls. RA was additionally associated with restrictive patterns (odds ratio [OR] 1.36 [95% CI 1.21, 1.52]) and obstructive patterns (OR 1.21 [95% CI 1.07, 1.37]) independent of confounders, and was most strongly associated with severe restrictive and obstructive patterns.ConclusionRA is associated with increased odds of restrictive and obstructive patterns, and this relationship is not explained by confounders, including smoking status. In addition to restrictive lung disease, clinicians should also be aware that airway obstruction may be a pulmonary manifestation of RA.
Technological advances in elite marathon performance
Senefeld, Jonathon W. , Haischer, Michael H. , Jones, Andrew M. , Wiggins, Chad C. , Beilfuss, Rachel, Joyner, Michael J. , Hunter, Sandra K. , Hunter, Sandra K , Jones, Andrew M , Wiggins, Chad C , Joyner, Michael J , Senefeld, Jonathon W

Mayo Clinic

Journal of Applied Physiology | May 13, 2021 | Volume: 130 | Issue: 6 | Pages: 2002-2008

10.1152/japplphysiol.00002.2021 | PMID 33982594 Get It

World-class athletes are substantively faster, wearing marathon racing shoes with technological advancements than other shoes when competing in the marathon. Our findings suggest that technological advances in footwear contributed to the recent improvements in marathon finishing times among elite runners and in record-setting marathon performances. This investigation highlights the importance of sports analytics and may have broad implications for the regulation of running footwear during competition.
Efficacy of erenumab in chronic migraine patients with and without ictal allodynia
Buse, Dawn C. , Koukakis, Reija, Klatt, Jan , Cheng, Sunfa , Chou, Denise E. , Lipton, Richard B. , Burstein, Rami , Dodick, David W.

Mayo Clinic

Cephalalgia | May 13, 2021 | Volume: 41 | Issue: 11-12 | Pages: 1152-1160

10.1177/03331024211010305 | PMID 33982623 Get It

Background Ictal cutaneous allodynia, common in chronic migraine, is associated with reduced responses to acute treatment with triptans. Allodynia’s impact on the efficacy of newer preventive treatments such as erenumab is unknown. Methods Post-hoc subgroup analysis of a double-blind, randomized, placebo-controlled 12-week study of erenumab in chronic migraine, contrasting those with no allodynia with those with moderate-severe allodynia assessed with the Allodynia Symptom Checklist-12, was undertaken. Results Of 648 randomized individuals with baseline Allodynia Symptom Checklist-12 scores, 386 (59.6%) had no allodynia and 153 (23.6%) had moderate-to-severe allodynia. Mean (standard deviation) baseline monthly migraine days were 17.6 (4.8) and 18.9 (4.3), respectively. Compared to placebo, the erenumab group had greater reductions in monthly migraine days and monthly acute migraine-specific medication days in both no allodynia and allodynia subgroups. Mean (95% confidence interval) treatment differences in change from baseline for monthly migraine days at week 12 were −2.5 (−3.7, −1.4) in the no allodynia subgroup and −3.3 (−5.3, −1.3) in the moderate-severe allodynia subgroup. Change in acute migraine-specific medication days were −3.3 (−4.3, −2.3) and −2.5 (−4.3, −0.8), respectively. Conclusions Erenumab’s efficacy in reducing monthly migraine days and acute migraine-specific medication days in chronic migraine was not impacted by the presence of moderate-severe ictal allodynia. Trial registration: ClinicalTrials.gov NCT02066415